Neuroscience-focused BioXcel Therapeutics has appointed Matt Wiley as SVP and chief commercial officer (CCO), the biotech said Wednesday.
He brings over 25 years of commercial and industry expertise across multiple product launches, including neuroscience products.
Formerly CCO at Vyne Therapeutics, a dermatology drugmaker, Wiley’s career highlights include a stint as VP of marketing at Jazz Pharmaceuticals, where he led the sleep medicines unit.
While there, he directed the go-to-market strategy and marketing for Jazz’s narcolepsy med Sunosi upon its 2019 launch (it’s subsequently been approved for use with sleep apnea, too), and developed the growth strategy for older narcolepsy blockbuster Xyrem. He also served as VP of marketing at Azur Pharma, supporting the startup’s US operations and eventual acquisition by Jazz.
BioXcel is preparing for its first potential approval and commercial launch, BXCL501 for the acute treatment of agitation associated with schizophrenia and bipolar disorders. The drug is slated for an FDA decision by April 5th.
